. 2005 Sep;79(17):11151–11160. doi: 10.1128/JVI.79.17.11151-11160.2005

TABLE 1.

Characteristics of patients and isolates

Patient category according to viral phenotype^a	Patient no.	Isolate no.	Time of isolation (mo from infection)^b	CD4⁺ T-cell count (10⁶ cells/liter) at time of isolation	Antiretroviral therapy at time of isolation^c	Loss of CD4⁺ T cells (10⁶ cells/liter/mo)	p24 in serum		First appearance of clinical symptom^e(mo from infection)^c
Patient category according to viral phenotype^a	Patient no.	Isolate no.	Time of isolation (mo from infection)^b	CD4⁺ T-cell count (10⁶ cells/liter) at time of isolation	Antiretroviral therapy at time of isolation^c	Loss of CD4⁺ T cells (10⁶ cells/liter/mo)	Follow-up (mo from infection)^b	Results/no. of tests^d	First appearance of clinical symptom^e(mo from infection)^c
Nonswitch	435	1577	67	510		−5.7	62-89	Neg/4	99
		3415	87	290
	1047	314	41	630		−4.6	48-62	Neg/3	71
		4223	89	574				Pos/1
	1838	5379	85	410		−2.9	35-140	Neg/6	131
		8590	121	290
Switch	2112	171	15	340		−4.8	31-68	Pos/10	23
		1156	31	370
		3502	57	338	AZT
	2242	1886	45	180		−5.2	33-84	Pos/11	18
		3700	64	213	AZT

Nonswitch, patients with virus that used only CCR5 throughout the study; Switch, patients with a detected switch to R5X4 virus.

The infection date is calculated as the midpoint between the last negative and the first positive samples.

AZT, zidovudine.

HIV-1 antigen enzyme-linked immunosorbent assay (Abbott, Stockholm, Sweden). Neg, negative; Pos, positive.

The first clinical symptom to appear in patient 435 was perianal herpes infection; in 1838 it was septic arthritis; in 1047 it was oral candidiasis; and in 2242 and 2112 it was persistent generalized lymphadenopathy.